NaviFUS System
Sponsors
NaviFUS Corporation, Genovate-NaviFUS (Australia) Pty Ltd., University of Cincinnati
Conditions
Brain TumorDrug Refractory EpilepsyDrug Resistant EpilepsyEpilepsyEpilepsy, Drug RefractoryEpilepsy, Drug ResistantEpilepsy, IntractableEpilepsy, Temporal Lobe
Phase 1
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
Not yet recruitingNCT06329570
Start: 2024-07-01End: 2027-03-31Target: 10Updated: 2024-03-26
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RecruitingNCT06388707
Start: 2024-09-13End: 2025-12-31Target: 8Updated: 2025-05-13
Unknown Phase
Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients
CompletedNCT03626896
Start: 2018-08-17End: 2019-06-19Updated: 2019-06-21
Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy
CompletedNCT03860298
Start: 2019-06-17End: 2020-10-14Updated: 2020-11-13
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
CompletedNCT04446416
Start: 2020-07-21End: 2023-08-04Updated: 2023-09-06
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
NCT04988750
Start: 2021-09-23End: 2025-01-31Target: 8Updated: 2023-09-06
NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
NCT04999046
Start: 2021-09-01End: 2024-06-30Target: 12Updated: 2023-09-06
Evaluation of the NaviFUS System in Drug Resistant Epilepsy
RecruitingNCT05947656
Start: 2023-10-02End: 2026-07-01Target: 18Updated: 2025-07-03
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
Not yet recruitingNCT07274787
Start: 2026-01-01End: 2029-06-01Target: 10Updated: 2025-12-10